Sign In
Buy HIMS
$28.01
+0.500 (+1.82%)
At Close: Jun 04, 2026
Hims & Hers Looks Like Hyper Growth At A Reasonable Price
10:52pm, Wednesday, 10'th Sep 2025
Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATRE
Hims & Hers Bets On Hormonal Health To Revive Investor Confidence
11:13am, Wednesday, 10'th Sep 2025
Hims & Hers Health Inc. HIMS launched a new category in men's health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.
Hims & Hers: The Next Chapter For Investors
10:15am, Wednesday, 10'th Sep 2025
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a b
Hims & Hers launches treatment plans for low testosterone
09:39am, Wednesday, 10'th Sep 2025
Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.
Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
09:00am, Wednesday, 10'th Sep 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men's health, offering access to innova
Hims & Hers Health Expands Testosterone Offerings
08:50am, Wednesday, 10'th Sep 2025
Hims & Hers Health is launching treatments for low testosterone on its telehealth platform, venturing deeper into a category often marred by stigma, according to its chief executive.
Trump aims to curb direct-to-consumer ads for drugs. Hims & Hers Health could be targeted.
07:12pm, Tuesday, 09'th Sep 2025
President Donald Trump's administration on Tuesday rolled out an executive action aimed at limiting direct-to-consumer advertising for pharmaceuticals, with officials saying a recent Hims & Hers Healt
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Tuesday, 09'th Sep 2025
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.79, marking a -3.73% move from the previous day.
Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem
12:11pm, Monday, 08'th Sep 2025
HIMS expands its digital health footprint with global moves, top-tier partnerships and more than 1,500 providers.
Hims & Hers Health: At The Intersection Of Secular Megatrends
05:58pm, Friday, 05'th Sep 2025
Hims & Hers Health, Inc. remains a Strong Buy as it is well-positioned to capitalize on secular wellness and digital health trends favored by younger generations. The company boasts stellar fundamenta
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
05:32pm, Tuesday, 02'nd Sep 2025
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HIMS' Personalized Wellness Platform Expands Preventive Care Access
02:16pm, Tuesday, 02'nd Sep 2025
Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.
Hims & Hers Health: Still Undervalued
03:24am, Sunday, 31'st Aug 2025
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short int
Hims & Hers: The Dominant Health Platform Of The Future
06:26pm, Friday, 29'th Aug 2025
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confir
